Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients
Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of International Journal of Geriatrics
2025-01-01
|
| Series: | Guoji laonian yixue zazhi |
| Subjects: | |
| Online Access: | http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.019&lang=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592769837694976 |
|---|---|
| author | Xueting Hou Jizhang Bao |
| author_facet | Xueting Hou Jizhang Bao |
| author_sort | Xueting Hou |
| collection | DOAJ |
| description | Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches. |
| format | Article |
| id | doaj-art-1500f11f842445319492330fdde8dae8 |
| institution | Kabale University |
| issn | 1674-7593 |
| language | zho |
| publishDate | 2025-01-01 |
| publisher | Editorial Office of International Journal of Geriatrics |
| record_format | Article |
| series | Guoji laonian yixue zazhi |
| spelling | doaj-art-1500f11f842445319492330fdde8dae82025-01-21T02:59:39ZzhoEditorial Office of International Journal of GeriatricsGuoji laonian yixue zazhi1674-75932025-01-014619610010.3969/j.issn.1674-7593.2025.01.019Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patientsXueting Hou0Jizhang Bao1Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.019&lang=enacute myelogenous leukemiaindividualized treatmenttargeted therapyimmunotherapy |
| spellingShingle | Xueting Hou Jizhang Bao Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients Guoji laonian yixue zazhi acute myelogenous leukemia individualized treatment targeted therapy immunotherapy |
| title | Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| title_full | Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| title_fullStr | Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| title_full_unstemmed | Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| title_short | Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| title_sort | current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients |
| topic | acute myelogenous leukemia individualized treatment targeted therapy immunotherapy |
| url | http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.019&lang=en |
| work_keys_str_mv | AT xuetinghou currentdevelopmentsinpersonalizedtreatmentstrategiesforelderlyacutemyelogenousleukemiapatients AT jizhangbao currentdevelopmentsinpersonalizedtreatmentstrategiesforelderlyacutemyelogenousleukemiapatients |